Zacks Investment Research upgraded shares of ECHO THERAPEUT (ECTE) from UNDERPERFORM to NEUTRAL on July 05, 2012, with a target price of $1.80.
Echo Therapeutics, Inc., a medical device and specialty pharmaceutical company, develops a non-invasive and wireless transdermal continuous glucose monitoring system for people with diabetes and for use in hospital critical care units in the United States. Its Symphony transdermal continuous glucose monitoring System is a non-invasive, wireless, designed to provide reliable, on-demand blood glucose data conveniently, continuously and cost-effectively. The company is based in Franklin, Massachusetts.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ECHO THERAPEUT (ECTE),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment